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Risperidone-induced weight gain and reduced locomotor activity in juvenile
female rats: the role of histaminergic and NPY pathways
Abstract
Second generation antipsychotic drugs (SGAs) such as risperidone are increasingly prescribed (mostly
for off-label use) to children and adolescents for treating various mental disorders. SGAs cause serious
weight gain/obesity and other metabolic side-effects. This study aimed to establish an animal model of
risperidone-induced weight gain in female juvenile rats, and to investigate the effects of risperidone on
the expression of hypothalamic histaminergic H1 receptors (H1R) and neuropeptides, and their
association with weight gain. Female Sprague Dawley rats were treated orally with risperidone (0.3 mg/kg,
3 times/day) or vehicle (control) starting from postnatal day (PD) 23 (±1 day) for 3 weeks (a period
corresponding to the childhood-adolescent period in humans). In the female juvenile rats, risperidone
treatment increased food intake and body weight gain, which started to appear after 12 days' treatment.
Risperidone also significantly decreased the locomotor activity of the female rats. Consistently,
risperidone significantly elevated mRNA expression of hypothalamic H1R, neuropeptide Y (NPY), and
agouti-related peptide (AgRP) compared to controls, and H1R and NPY levels were correlated with
risperidone enhanced weight gain and food intake in the female juvenile rats. However, risperidone did not
affect hypothalamic proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript
(CART) mRNA expression. Therefore, these results suggested that risperidone elevated appetite and body
weight gain in juveniles via regulation of the hypothalamic H1R, NPY and AgRP pathways, as well as by
reducing activity.
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Abstract
Second Generation Antipsychotic drugs (SGAs) such as risperidone are increasingly
prescribed (mostly for off-label use) to children and adolescents for treating various mental
disorders. SGAs cause serious weight gain/obesity and other metabolic side-effects. This
study aimed to establish an animal model of risperidone-induced weight gain in female
juvenile rats, and to investigate the effects of risperidone on the expression of hypothalamic
histaminergic H1 receptors (H1R) and neuropeptides, and their association with weight gain.
Female Sprague Dawley rats were treated orally with risperidone (0.3 mg/kg, 3 times/day) or
vehicle (control) starting from postnatal day (PD) 23 (±1 day) for 3 weeks (a period
corresponding to the childhood-adolescent period in humans). In the female juvenile rats,
risperidone treatment increased food intake and body weight gain, which started to appear
after 12 days’ treatment. Risperidone also significantly decreased the locomotor activity of
the female rats. Consistently, risperidone significantly elevated mRNA expression of
hypothalamic H1R, neuropeptide Y (NPY), and agouti-related peptide (AgRP) compared to
controls, and H1R and NPY levels were correlated with risperidone enhanced weight gain and
food intake in the female juvenile rats. However, risperidone did not affect hypothalamic
proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART)
mRNA expression. Therefore, these results suggested that risperidone elevated appetite and
body weight gain in juveniles via regulation of the hypothalamic H1R, NPY and AgRP
pathways, as well as by reducing activity.

Key Words: risperidone; weight gain; juvenile rats; histamine receptor; neuropeptide Y;
locomotor activity
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LIST OF ABBREVIATIONS
5-HT2AR, serotonergic 5-HT2A receptor
5-HT2CR, serotonergic 5-HT2C receptor
AgRP, agouti-related peptide

Arc, arcuate nuclei
CART, cocaine- and amphetamine-regulated transcript
D2R, dopaminergic D2 receptor
H1R, histaminergic H1 receptor
NPY, neuropeptide Y

PD, postnatal day
POMC, proopiomelanocortin

qRT-PCR, quantitative real-time polymerase chain reaction
SGAs, second generation antipsychotics
VMH, ventromedial nucleus
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1. Introduction
Over recent decades, antipsychotic prescriptions have sharply increased, not only to treat
childhood-onset schizophrenia, but have also been widely used in children and adolescents to
treat mental disorders such as bipolar disorder, autism and attention deficit hyperactivity
disorder [1-4]. The majority of antipsychotic drugs prescribed in children and adolescents are
second generation antipsychotics (SGAs) including risperidone and olanzapine, which have
serious weight gain and other metabolic side-effects [5-10]. Of even greater concern,
however, is evidence clearly demonstrating that the paediatric population appears to be at
greater risk than adults for SGA-induced weight gain and metabolic side-effects [11].

Risperidone is the most commonly prescribed antipsychotic drug in paediatric patients [4, 12,
13]. It has been repeatedly reported that risperidone is associated with much higher weight
gain in children and adolescents than those in adults [14-17]. For example, a meta-analysis of
placebo controlled trials over 3000 paediatric and adult subjects using risperidone found that
it can cause over three times more body weight gain (by percentage of weight changes) in
youths than in adults [18]. A clinical trial also confirmed that after an average of 2.9 years’
of risperidone treatment, 99 children and adolescent patients suffered a significant weight
gain and increased body mass index (BMI) [19].

In contrast to first generation antipsychotics (such as haloperidol) that are largely potent and
selective dopamine D2 receptor (D2R) antagonists, SGAs have binding affinities for various
neurotransmitter receptors, such as D2R, serotonin 5-HT2A (5-HT2AR) and 5-HT2C receptors
(5-HT2CR) and histamine H1 receptors (H1R) [20]. Accumulated evidence from our
laboratory and other laboratories has revealed that dopamine D2R and 5-HT2AR play a critical
role in the therapeutic effects of SGAs including risperidone, while 5-HT2CR and H1R
4

contribute to weight gain/obesity side-effects [21-24]. In particular, using an adult rat model
for olanzapine-induced weight gain, we previously identified that hypothalamic H1R is a key
factor for the olanzapine-induced weight gain side-effect [25, 26]. Since risperidone is also a
potent antagonist for H1R [20], H1R may also play a key role in risperidone-induced weight
gain.

Using the adult female rat model for antipsychotic-induced weight gain, it has been
repeatedly revealed that olanzapine elevated the expression of appetite stimulating
neuropeptides in the hypothalamus, including neuropeptide Y (NPY) and agouti-related
peptide

(AgRP),

while

decreasing

appetite

inhibiting

neuropeptides

such

as

proopiomelanocortin (POMC) [25, 27-29]. On the other hand, H1R is independent of POMC
regulation [30], but links to NPY expression [31]. Evidence has also shown that increased
activities of NPY and AgRP expression by olanzapine were through blocking the H1R [25, 26,
32]. There have been two previous studies investigating the effects of risperidone on
expression of hypothalamic neuropeptides in male rats, however the results were
contradictory and puzzling [33, 34]. Ota and his colleagues found that 3-week treatment of
risperidone in adult male rats did not have any effect on the expression of hypothalamic NPY,
AgRP, POMC and CART, even though treatment increased food intake [33, 35]. The other
study reported some puzzling results in four-week old male rats; although food intake
increase and weight gain were observed, four weeks’ treatment of risperidone significantly
decreased both appetite stimulating neuropeptides (NPY and AgRP) and appetite inhibiting
neuropeptide POMC, while the other appetite inhibiting neuropeptide CART mRNA
expression was increased [34]. Gothelf and colleagues revealed that after 4 weeks’ of
antipsychotic administration to male adolescent schizophrenic inpatients, BMI was
significantly enhanced in those treated with olanzapine, but not in those treated with
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haloperidol, which was associated with an increase in caloric intake [36]. Another study
found that first-attack psychotic patients had reduced plasma levels of NPY and αmelanocyte melanocytestimulating hormone (α-MSH), but an increased plasma CART level
compared to the control; four weeks’ risperidone treatment did not change circulating NPY,
α-MSH, and CART levels [8]. A recent review paper demonstrated that the effect of SGAs
including risperidone is associated with food intake, physical activity and energy expenditure
in both children and adult patients [37].

To date, there has been no study investigating the hypothalamic regulatory mechanisms
underlying risperidone-induced weight gain in female juvenile rats. Therefore, in this study,
we investigated the effects of risperidone on body weight and food intake in female juvenile
rats and further investigated its effects on expression of hypothalamic H1R, NPY, POMC,
AgRP and CART mRNA expression, and their relationships with changes in body weight
gain and food intake. Since our recent studies in adult rat models have demonstrated that
olanzapine-induced weight gain is associated with a significant decrease in locomotor activity
[38-40], and decreased activity was also observed after acute administration of antipsychotics
during early development [41], the locomotor activity of female juvenile rats was also
examined in this study.

2. Materials and Methods
2.1 Animals Housing, Administration and Drug Treatment
Timed pregnant Sprague Dawley rats (at gestation day 16) were obtained from the Animal
Resources Centre (Perth, WA, Australia). They were housed in individual cages and allowed
ad-libitum access to standard laboratory chow diet (3.9 kcal/g: 10% fat, 74% carbohydrate,
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16% protein) and water under a light (07:00 to 19:00) and dark (19:00 to 7:00) cycle and
temperature control (22ºC) throughout the experiment [32, 38]. Day of birth was recognised
as postnatal day (PD) 0. Pups were sexed on PD14, and 24 female rats were weaned on PD21
and housed in individual cages.

Before the treatment procedures, rats were trained for self-administration of the drug by
feeding them using 0.3 g cookie dough (including 30.9 % cornstarch, 30.9% sucrose, 6.3%
gelatine, 15.5% casein, 6.4% fibre, 8.4% minerals and 1.6% vitamins) without drug twice a
day during PD18-21. The postnatal female rats (PD23±1) were then randomly assigned to
one of two treatment groups as follows: (1) risperidone (0.3 mg/kg, t.i.d., Janssen, USA;
n=12) or (2) vehicle (control; n=11) for 3 weeks (a period corresponding to the childhoodadolescent period in humans) [42]. Drugs were prepared in advance by mixing with cookie
dough pellets and droplets of water, and were administered 3 times per day (8±1 hours,
interval) orally for 3 weeks [32, 38]. The rats in the control group received an equivalent
pellet without drug. Rats were observed throughout the experiment to ensure all cookie dough
pellets were consumed. Body weight, food intake and water intake were measured and
recorded once every two days. This study was approved by the Animal Ethics Committee,
University of Wollongong, Australia (AE12/20); and all the procedures complied with the
Australian Code of Practice for the Care and Use of Animals for Scientific Purposes (2004).

After completing treatment, all rats were sacrificed (without fasting) by carbon dioxide
asphyxiation. Brain samples were collected and stored in a -80 ºC freezer until analysis. The
hypothalamic nuclei were dissected based on the rat brain atlas [43]. In brief, rat brains were
cut at −10.5 °C ± 1.5 °C into 500µm coronal sections. The nuclei were dissected using micropunches (57401, Stoelting Co, USA), targeted at the arcuate nuclei (Arc). Since the Arc is
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small, the punched tissue primarily contained Arc, but included adjacent ventromedial
nucleus (VMH), therefore the punched tissue was labelled as the mediobasal hypothalamus.
The dissected tissue was placed into 1.5 ml Eppendorf tubes, and stored at −80 °C until use
for qRT-PCR [25].

2.2 Open Field Test
An open field test was performed on PD36 ± 1 day in order to determine whether risperidone
could affect the locomotor activity of rats. A rat was placed in the centre of a black
rectangular arena (60 × 60 cm2, 40 cm high) that was exposed to lighting of 25 lux across the
entire arena. A video camera was used to record the behaviour of the rats for 30 minutes from
the central top of the arena. The locomotor activity of the rats was analysed using EthoVision
Color-Pro software (Noldus Information Technology, Wageningen, The Netherlands) [38]
and the distance moved (cm) and velocity (cm/s) were measured.

2.3 Quantitative real-time PCR
Quantitative real-time polymerase chain reaction (qRT-PCR) was applied to detect mRNA
expression of H1R, NPY, POMC, AgRP and CART in the mediobasal hypothalamus. Total
RNA was isolated using a PureLinkTM RNA extraction kit (Invitrogen Life Technologies,
Carlsbad, CA, USA). RNA quality was then assessed by Nanodrop (ThermoFisher Scientific,
MA, USA). Aliquots of total RNA were digested within a spin column RNase-free DNase I
kit (MO BIO Laboratories, Inc., CA, USA) to remove residual genomic DNA. The digested
RNA was purified by ethanol precipitation, dried and dissolved in RNA Storage Solution
(Ambion, Inc., Austin, TX). Aliquots of RNA were subjected to reverse transcription using
super-script II RNase H-Reverse Transcriptase. To ensure the total RNA was free from
genomic DNA after DNase digestion, aliquots of total RNA were subjected to PCR using a

8

pair RT-control. First-strand cDNA was synthesised from RNA with Superscript® VILOTM
cDNA synthesis kit (Life Technologies, NSW, Australia) with 20 µL reaction volume
containing 9 µL cDNA, 10 µL SYBR Green PCR Master Mix (Applied Biosystems, Boston,
MA), 1 µL each of primers.

Real-time quantitative PCR was performed in triplicate using TaqMan® Gene Expression
Assays (Applied Biosystems, Foster City, USA) in combination with continuous SYBR
Green detection (Applied Biosystems) on LightCycler®480 (Roche, Penzberg, Germany).
The assay (Life Technologies, NSW, Australia) identifications of the target genes were H1
receptor (Rn00566691 s1); NPY (Rn01410145 m1); POMC (Rn00595020 m1); AgRP
(Rn01431703 g1), and CART (Rn01645174 m1). β-actin (Rn00667869 m1) and GAPDH
(Rn01775763 g1) were expressed as endogenous controls. The RT-PCR plates were run by
polymerase amplification for 10 mins at 95 ºC, followed by 40 cycles of denaturation at 95 ºC
for 15s, and annealing and extending at 60 ºC for 1 min. The 2−∆∆T method was used to
calculate the results [44].

2.4 Statistical Analysis
Statistical analysis was performed using SPSS (IBM version 19.0, SPSS Inc., NY, USA). The
Kolmogorov-Smirnov test was used to examine the distribution of data from all experiments.
Weight gain, food intake and water intake data were analysed by two-way repeated ANOVAs
(Treatment × Days as repeated measures). Behavior and mRNA expression were analyzed by
independent-samples T test to compare the risperidone and control groups. Pearson’s
correlation test was used to analyse the relationships among the measurements. All data were
expressed as mean ± SEM, and statistical significance was accepted when p<0.05.
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3. Results
3.1 Effects of risperidone on body weight gain, food intake and water intake
Risperidone had no effects on weight gain in the first 12 days of drug treatment (Figure 1A),
however it was shown that body weight gain was significantly greater in the risperidone
group compared to the controls from day 14 (Figure 1A). Two-way repeated ANOVAs
(Treatment × Days as repeated measures) showed significant main effects of Days
(F3,63=193.915, p<0.001), Treatment (F1,21=8.939, p<0.01), and significant interaction
between the two factors (F3,63=5.484, p<0.01) on accumulated body weight gain. Risperidone
significantly increased the accumulated body weight gain on treatment day 14 (t=-2.535,
df=21, p=0.019), day 16 (t=-2.712, df=21, p=0.013), day 18 (t=-3.345, df=21, p=0.003) and
day 20 (t=-2.534, df=21, p=0.018) (Figure 1A). There was no significant difference between
risperidone and control groups in leg length (Risperidone, 4.55±0.04 cm vs. Control,
4.43±0.06 cm; t=-1.562, df=21, p=0.133).

Consistent with the weight gain data, there was no difference in food intake on the first 12
days’ of drug treatment, while risperidone-treated juvenile rats showed significant enhanced
accumulated food intake compared with controls during treatment days 14-20 (Figure 1B).
There were significant main effects of Treatment (F1,21=6.222, p<0.05) and Days
(F3,63=865.998, p<0.001), and significant interaction between the two factors (F3,63=3.895,
p<0.05) (Figure 1B). Risperidone-treated juvenile rats also had higher average feeding
efficiency (accumulated body weight gain/accumulated food intake during treatment days 1420) than the control (t=-2.707, df=21, p=0.013) (Figure 1C). Moreover, there were highly
positive correlations between total body weight gain and total food intake (r=0.581, p<0.01),
and with feeding efficiency (r=0.614, p<0.01).
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There was also no change of water intake in the first 12 days’ of treatment. From treatment
day 14 (Figure 1D), the two-way repeated ANOVAs (Treatment × Days as repeated measures)
also showed the significant main effects of Treatment (F1,21=5.503, p<0.05) and Days
(F3,63=642.025, p<0.001), but there was no significant interaction between the two factors
(F3,63=0.738, p=0.533). There was a significant difference of water intake between
risperidone treatment and control on treatment day 14 (t=-2.376, df=21, p=0.027), day 16 (t=2.457, df=21, p=0.023), day 18 (t=-2.451, df=21, p=0.023), and day 20 (t=-2.447, df=21,
p=0.023) (Figure 1D).

3.2 Effects of risperidone treatment on locomotor activity
Figure 2A shows examples of locomotor activity of rats treated with risperidone and vehicle
(controls). Compared to the control, the rats treated with risperidone had significantly
decreased total distance moved (t=2.951, df=21, p<0.01) and total lower velocity (t=3.310,
df=21, p<0.01) (Figures 2B and C). Furthermore, it is important to note that total distance
moved was negatively correlated with total body weight gain (r=-0.569, p<0.01), and feeding
efficiency (r=-0.444, p<0.05). The velocity also negatively correlated with total body weight
gain (r=-0.610, p<0.01), and feeding efficiency (r=-0.474, p<0.05).

3.3 Effects of risperidone treatment on expression of hypothalamic H1R, NPY, POMC,
AgRP and CART
Figure 3 presents the effects of risperidone treatment on the mRNA expression of
hypothalamic H1R, NPY, POMC, AgRP and CART in female juvenile rats compared with
the control. Risperidone treatment significantly upregulated mRNA expression of H1R (+23%,
t=-3.784, df=9, p=0.004) and AgRP (+155%, t=-2.917, df=9, p=0.021), and a tendency to
elevate NPY (t=-2.124, df=9, p=0.055), compared with the control (Figure 3). Hypothalamic
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H1R mRNA expression was positively correlated to NPY (r=0.579, p<0.05) and AgRP
(r=0.565, p<0.05) levels. There were positive correlations between hypothalamic NPY
expression and body weight gain (r=0.678, p<0.05), and feeding efficiency (r=0.560, p<0.05).

4. Discussion
This study revealed the effects of risperidone treatment on body weight, food and water
intake, locomotor activity, and mRNA expression of H1R and hypothalamic neuropeptides
POMC, NPY, AgRP and CART in juvenile (PD23-44) female rats. To our knowledge, this is
the first study into the effects of risperidone on hypothalamic appetite signalling in a young
female rat model of risperidone-induced weight gain. Our results showed that risperidone
treatment at 0.3 mg/kg, t.i.d. (equivalent to the recommended dosage in the clinic)
significantly increased body weight gain in female juvenile rats. We found that risperidoneinduced weight gain and food intake was associated with increased histamine H1R and NPY
levels in the hypothalamus. Furthermore, our results showed that risperidone-induced weight
gain is associated with a significant decrease in locomotor activity in juvenile female rats.
Our findings coincide with previous reports on children/adolescents [17, 45-48].

4.1 Choice of female rats
Female rats were chosen in this study, both because risperidone-induced weight gain has
been reported in a previous study using female juvenile rats [49] and also because, while
SGA-induced weight gain has been consistently established in females using various SGAs
including risperidone and olanzapine [27, 32, 38, 40, 50-53], it could not be consistently
modelled in male rodents. While risperidone-induced weight gain has been well modelled in
female rodents [49, 52-54], it has been established in male rats in some studies [34] but not
in others [35, 54, 55].
12

4.2 Late onset of weight gain
The increase in weight gain and food intake caused by risperidone treatment in this study
occurred after 12 days’ treatment. This was unexpected, since previous studies in adult
models often showed that risperidone and olanzapine increased food intake and weight gain
after 3-4 days’ treatment [38, 52, 54, 56]. Risperidone was also reported to increase food
intake and body weight after 3 days’ treatment in female rats at 7-weeks old [49]. In this
study, however, much younger female animals (23-days old) were used. These results
suggest a possible age difference in the onset of increased weight gain and food intake
caused by risperidone treatment, although we could not fully explain it at this stage. Further
study is needed to address this issue.

4.3 Dosage
According to dosage translation between humans and rats based on body surface following
the FDA guideline for clinical trials [57, 58], the risperidone dosage in this study (0.3 mg/kg)
is equivalent to the human dosage (1.8 mg in human children at 25 kg body weight, or 2.8
mg in human children at 40 kg body weight). The half-life of active moiety (including
risperidone and 9-hydroxyrisperidone) is 8.6 hours in the rat brain and 11.4 hours in rat
plasma after an oral dose risperidone [59], compared to an average 20 hours in human
plasma (up to 30 hours in poor metabolisers) [60]. This drug was therefore delivered orally 3
times/day (at 8 hour intervals) in this study to ensure a consistently high concentration that
better mirrors the human scenario of oral administration [38]. The risperidone (0.3 mg/kg,
t.i.d.) used in this study is therefore within the range of recommended dosage used in
paediatric patients (0.5-3 mg/day) [1, 4, 60], and does not reach the maximum indicated
paediatric dosage (6 mg/day) [61]. At this dosage, the risperidone drug treatment reaches
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between 65-90% dopamine D2 receptor occupancy [62, 63]. Risperidone treatment at 0.5
mg/kg (once daily, intraperitoneal or subcutaneous injection) has been reported to
significantly increase weight gain and food intake in female adult/7-week old rats [49, 52, 54]
and in female adult mice risperidone (2 mg/kg, orally twice per day) for 3 weeks led to
significantly increased body weight gain and food intake compared to controls [53].

4.4 Hypothalamic H1R mRNA expression
Histamine H1R is highly expressed in the hypothalamic Arc and VMH, which play significant
roles in body weight regulation, food intake and energy expenditure [64, 65]. Two metaanalyses of clinical data have found that the H1R antagonistic property of antipsychotics is
strongly correlated with their body weight gain side-effect [66, 67]. Studies in animal models
have

further

evidenced

that

hypothalamic

H1R

is

a

major

contributor

for

olanzapine/clozapine-induced weight gain and obesity [25, 26, 32, 68, 69]. Risperidone has
high binding affinity with H1R [20], and our examination of mRNA expression of
hypothalamic H1R found a significant increase in hypothalamic H1R mRNA expression in the
risperidone treatment group. This result is consistent with previous findings that olanzapine
(a potent H1R antagonist) increased hypothalamic H1R mRNA expression associated with
olanzapine-induced weight gain [25, 26].

4.5 mRNA expressions of hypothalamic neuropeptides
In this study, we revealed that hypothalamic NPY and AgRP mRNA expression were
elevated by risperidone treatment in young female rats, which were correlated with
risperidone-induced food intake and weight gain. This is also consistent with previous reports
in female rat models for olanzapine-induced weight gain with a significant increase of NPY
mRNA expression [25, 27-29, 70]. In addition, it has previously been found that acute ICV
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olanzapine treatment led to an upregulated AgRP level in male adult rats [17]. Furthermore,
our recent study showed an elevated AgRP mRNA expression after two weeks’ treatment
with olanzapine in female adult rats [25]. Corresponding with our findings, Gruber and
colleagues reported that NPY-like immunoreactivity was increased in the hypothalamic
region but decreased in the ventral striatum of male Wistar rats (weighing 130 g at the
beginning of the experiment) after 4-weeks’ risperidone treatment [71]. However, results
contradictory to this study were reported in one recent study, where 4 weeks’ treatment of
risperidone in 4-week old male rats caused a decrease in hypothalamic NPY/AgRP
expression; instead, there was a significant decrease in hypothalamic POMC mRNA
expression induced by risperidone treatment, while CART mRNA expression increased [34].
In view of the fact that hypothalamic NPY and AgRP are appetite stimulating neuropeptides,
and POMC and CART are appetite inhibiting neuropeptides, these results are puzzling and
hard to explain, because a significant increase in weight gain and food intake was observed in
these risperidone treated male rats [34]. In this study, we did not find any changes in POMC
and CART mRNA expression after risperidone treatment in female juvenile rats. This was
different from previous findings in the olanzapine-induced weight gain model, in which
olanzapine treatment was found to decrease POMC mRNA expression in adult female rats
[25, 27-29, 70]. However, although first-attack psychotic patients had higher plasma NPY
and α-MSH, but lower CART levels than the control, four weeks’ risperidone treatment did
not change NPY, α-MSH, and CART levels [8]. Therefore, further studies are necessary to
investigate the mechanisms underlying risperidone-induced weight gain, particularly in
juveniles.

4.6 Reduced locomotor activity

15

It is worth noting that weight gain induced by antipsychotics is not only attributed to
increased energy intake; reduced energy expenditure may also play an important role as
proven in olanzapine-induced weight gain rat models [38, 39, 56, 72]. In fact, this study
found that risperidone reduced locomotor activity in juvenile female rats, which is consistent
with a number of studies in which risperidone was proven to reduce locomotor activity in
rats and mice [53, 73, 74]. Clinical studies have also reported that risperidone treatment
reduced hyperactivity in children with attention-deficit and bipolar disorder [37, 75, 76].
Therefore, the decreased activity exhibited in the present study may also play a role in
risperidone-induced body weight gain. Furthermore, this study found that risperidone
treatment also increased water intake, which might reflect the dry mouth side-effects
following risperidone treatment often observed in clinics [77].

5. Conclusion
Overall, this study has shown that oral risperidone treatment induced significantly increased
weight gain and food intake in juvenile female rats. Risperidone-induced body weight gain
and hyperphagia could be through regulating histamine H1R, NPY and AgRP signalling in
the hypothalamus, as well as reducing locomotor activity. Since weight gain and other
metabolic abnormalities during childhood could strongly predict adult obesity and metabolic
syndromes, paediatric subjects treated with antipsychotics such as risperidone face a much
greater risk of obesity and other metabolic disorders in adulthood, which pose a major risk of
premature cardiovascular morbidity and mortality in adults [78]. Therefore, further studies
using the animal model are important for developing strategies to ameliorate risperidoneinduced weight gain in juvenile patients, and to reveal its underlying mechanisms.
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Figure 1. The efffects of rissperidone ttreatment administratio
a
on on the accumulateed body
weight gain (A), food intakee (B), feediing efficien
ncy (C) and
d water inttake (D) off female
juvenilee rats. Rispperidone (0
0.3 mg/kg; n=12) or control (veehicle; n=111). ●: con
ntrol; ■:
risperiddone. * p<0..05, ** p<0.01 vs. conttrol.
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Figure 2. (A) Exxamples off locomotoor activity from femaale juvenilee rats treatted with
risperiddone or conttrol (vehiclee). (B) Totaal distance moved
m
and (C)
( Travel vvelocity in the
t open
field tesst, **p<0.011 vs. control.
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Figure 3. Effectss of risperiidone treatm
ment on th
he hypothalamic mRN
NA expresssions of
histaminne H1R, NP
PY, AgRP, POMC andd CART co
ompared wiith controls in female juvenile
rats. A
Abbreviationns: NPY, neuropeptid
n
de Y; AgR
RP, agouti-rrelated pepptide; POM
MC, proopiomeelanocortin; CART, cocaine- and amph
hetamine-reg
gulated traanscript. *p<0.05,
*
**p<0.001 vs. risperridone. Blacck bar: conttrol; White bar:
b risperid
done.
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